2nd Annual Pre-clinical and clinical safety tesing for new drugs

Summary

Attend this conference to:

• Gain a balanced overview of target organ toxicology and improve the predictability hepatic, renal, cardiac and CNS adverse event
• Hear how reducing acute toxicity testing can help you achieve your deadlines sooner and gauge current regulator attitudes on the emerging area
• Understand the paediatric investigation plan, what it means for your safety studies and how you can implement the solutions to ensure your juvenile toxicity tests are compliant with FDA and EMEA guidelines
• Discover how pharmaceutical and biotech companies are tackling the challenges of pre-clinical safety testing, real life insight from AstraZeneca, Pfizer, Novartis, Boehringer Ingelheim, F Hoffmann La Roche and Intendis GmbH and instructions from MHRA and BfArM